REG - Argent Biopharma Ltd - SINTEF Collaboration for Chronic Wound Management

Argent BioPharmaAnnouncement

21/08/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240821:nRSU1889Ba&default-theme=true

RNS Number : 1889B  Argent Biopharma Limited  21 August 2024

 

21 August 2024

 

Argent BioPharma Ltd.

(Argent BioPharma or the Company)

 

Strategic Collaboration with SINTEF for Advanced Chronic Wound Management

 

Argent BioPharma, an innovative multidisciplinary drug discovery company
within the biopharmaceutical sector, is pleased to announce a strategic
collaboration with SINTEF, one of Europe's largest independent research
organisations, to address the critical and unmet clinical challenge of chronic
wound management, through nano-formulations as part of the Company's ongoing
expansion into new therapeutic areas.

 

Argent Biopharma hopes that this collaboration with SINTEF will lead to
significant advancements in the treatment of chronic wounds, ultimately
improving the quality of life for patients suffering from this challenging
condition. The Company looks forward to updating shareholders as the project
progresses.

 

Project overview

 

Chronic wounds represent a significant clinical issue globally, causing
extreme patient suffering and affecting substantial numbers of individuals.
These wounds present complex challenges, including severe symptoms,
antibiotic- resistant infections, impenetrable biofilms, and deteriorating
local tissue health.

 

Argent BioPharma intends for this study to address multiple facets of this
complex condition as detailed below:

 

·    Identification and Selection of Novel Anti-Microbial Active
Ingredients:

o  Experiments performed with SINTEF will initially focus on identifying and
selecting the antimicrobial activities of a range of repurposed
polypharmacological agents endowed with multiple medically beneficial
activities.

·    Improving Local Tissue Health and Symptomatic Relief:

o  SINTEF will further investigate the chosen range of active ingredients for
their anti-biofilm, skin-health modifying and symptom alleviating functions.

·    Optimizing nano-formulations of the selected active ingredients to
enhance the derived medical benefits:

o  The composition of the particles will be modified in response to the
efficacy observed in the course of development, simultaneously with
modification of their additional pharmacological features.

 

The collaboration will be targeting chronic wound infections with an array of
various nano-encapsulated active ingredients. The precise selection and dosing
of these active ingredients will be methodically evaluated. The greater part
of the ingredients have not served previously as designated anti-microbial
agents, thus aligning with antimicrobial stewardship.

 

A significant aspect of this project is the design of nano-formulations for
the selected agents which are intended to be identified in the initial
screening experiments. Nano-formulation is expected to enhance the
pharmacological characteristics and efficacy of the resulting preparation via
improved drug delivery, increased penetration through biofilms, and sustained
release of active compounds, thereby addressing the challenges posed by
antibiotic resistance and local tissue health deterioration.

 

All costs applicable to the project will be incurred by Argent BioPharma,
although, it is not anticipated that these costs will have a material impact
on the Company's ongoing expenses. Additionally, Argent BioPharma will retain
ownership of all project results, including any intellectual property
developed.

 

-Ends-

 

Authorised for release by the board of directors, for further information
please contact:

 

 Argent BioPharma                                             Argent BioPharma

 Roby Zomer                                                   Rowan Harland

 CEO & Managing Director                                      Company Secretary

 +61 8 6555 2950                                              +61 8 6555 2950

 info@argentbiopharma.com (mailto:info@argentbiopharma.com)   info@argentbiopharma.co (mailto:info@argentbiopharma.co.uk) m

 

About Argent BioPharma

 

Argent BioPharma Limited (the "Company") (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an
innovative multidisciplinary drug development Company within the
biopharmaceutical sector.  The Company focuses on multidisciplinary methods
with Nanotechnology, developing multi-target therapies for comprehensive
disease management, especially concerning the central nervous system ("CNS")
and Immunology treatments.

 

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

 

About SINTEF

 

SINTEF is one of Europe's largest research institutes, with multidisciplinary
expertise within technology, natural sciences and social sciences. SINTEF is
an independent foundation which, since 1950, has created innovation through
development and research assignments for business and the public sector at
home and abroad.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDEAEPFAFPLEEA